# NovoCure Limited Ordinary Shares (NVCR)

NovoCure's Optune Pax therapy receives FDA approval for pancreatic cancer treatment, a significant milestone. Despite this positive news, the stock is experiencing downward pressure due to broader market trends.

### About NovoCure Limited Ordinary Shares
NovoCure Limited Ordinary Shares (NVCR) is a healthcare company focused on TTFields therapy for cancer treatment.  
NovoCure Limited Ordinary Shares uses the ticker $NVCR for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- NovoCure Limited Ordinary Shares (NVCR) social dominance hit [------] which is 1025% higher than it's daily average.
- NovoCure Limited Ordinary Shares (NVCR) mentions hit [---] which is 1109% higher than it's daily average.
- NovoCure Limited Ordinary Shares (NVCR) mentions near a 52-week high at [---].
- NovoCure Limited Ordinary Shares (NVCR) creators hit [---] which is 1021% higher than it's daily average.
- NovoCure Limited Ordinary Shares (NVCR) trading volume is up 182.93% from the previous week.
- NovoCure Limited Ordinary Shares (NVCR) social dominance is up 8000% from the previous [--] months.
- NovoCure Limited Ordinary Shares (NVCR) Galaxy Score™ is up 128.57% from the previous month.
- NovoCure Limited Ordinary Shares (NVCR) creators is up 1338.71% from the previous week.
- NovoCure Limited Ordinary Shares (NVCR) engagements is up 987.27% from the previous week.
- NovoCure Limited Ordinary Shares (NVCR) mentions is up 1156% from the previous week.
- NovoCure Limited Ordinary Shares (NVCR) posts created is up 6883.33% from the previous week.
- NovoCure Limited Ordinary Shares Creators hit a 52-Week high of [---] for the day
- NovoCure Limited Ordinary Shares Creators hit an all time of [---] for the day
- NovoCure Limited Ordinary Shares Engagements hit a 52-Week high of [-------] for the day
- NovoCure Limited Ordinary Shares Mentions hit a 52-Week high of [---] for the day

### Price: $11
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/close.tsv)  
Despite positive news like FDA approval for pancreatic cancer treatment, NVCR's price is experiencing downward pressure, likely due to broader market trends that are currently outweighing the positive social and corporate developments.  

24-Hour: -12.11%
7-Day: 7.75%
30-Day: -19.43%

1-Year High: $22.50 on 2025-02-16  
1-Year Low: $10 on 2026-02-09  
  
  
### AltRank: [---]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/alt_rank.tsv)  
NovoCure Limited Ordinary Shares (NVCR) is currently AltRank #625 based on combined combined social and market metrics
Daily Average: [-----]  
[--] Week: [---] [----]  
[--] Month: [---] [------]  
[--] Months: [---] [------]  
[--] Year: [---] [----]  
1-Year High: [-----] on 2026-01-29  
1-Year Low: [--] on 2025-11-01  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] +8  
[--] Month: [--] +36  
[--] Months: [--] +9  
[--] Year: [--] +35  
1-Year High: [--] on 2025-06-10  
1-Year Low: [--] on 2025-10-30  
  
  
### Engagements: [------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/interactions.tsv)  
Current Value: [------]  
Daily Average: [-----]  
[--] Week: [-------] +987%  
[--] Month: [-------] +573%  
[--] Months: [-------] +13%  
[--] Year: [---------] -59%  
1-Year High: [-------] on 2026-02-12  
1-Year Low: [--] on 2025-12-21  

Engagements by network (24h):
News: [--]
Reddit: [--]
TikTok: [--]
X: [------]
YouTube: [---]

  
  
### Mentions: [---] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/posts_active.tsv)  
Current Value: [---]  
Daily Average: [--]  
[--] Week: [---] +1,156%  
[--] Month: [---] +344%  
[--] Months: [-----] -8.20%  
[--] Year: [-----] -8.80%  
1-Year High: [---] on 2026-02-12  
1-Year Low: [--] on 2025-12-21  

Mentions by network (24h):
News: [--]
Reddit: [--]
TikTok: [--]
X: [---]
YouTube: [--]

  
  
### Creators: [---] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/contributors_active.tsv)  
[---] unique social accounts have posts mentioning NovoCure Limited Ordinary Shares (NVCR) in the last [--] hours which is up 7% from [---] in the previous [--] hours
Daily Average: [--]  
[--] Week: [---] +1,339%  
[--] Month: [---] +402%  
[--] Months: [---] -25%  
[--] Year: [-----] +30%  
1-Year High: [---] on 2026-02-12  
1-Year Low: [--] on 2025-12-21  

The most influential creators that mention NovoCure Limited Ordinary Shares in the last [--] hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@BiopharmIQ](/creator/twitter/BiopharmIQ)           | [--]    | [------]    | [--]     | [------]      |
| [@goldchart2](/creator/twitter/goldchart2)           | [--]    | [---]       | [--]    | [---]         |
| [@Stocktology](/creator/twitter/Stocktology)         | [--]    | [---]       | [--]     | [---]         |
| [@TohJah7809](/creator/twitter/TohJah7809)           | [--]    | [-----]     | [--]     | [---]         |
| [@marketrebellion](/creator/youtube/marketrebellion) | [--]    | [------]    | [--]     | [---]         |
| [@ATP_Analytics](/creator/twitter/ATP_Analytics)     | [--]    | [-----]     | [--]    | [---]         |
| [@NightOwlBiotech](/creator/twitter/NightOwlBiotech) | [--]    | [-----]     | [--]     | [---]         |
| [@HannaMiraftab](/creator/twitter/HannaMiraftab)     | [--]    | [------]    | [--]     | [--]          |
| [@jonnajarian](/creator/twitter/jonnajarian)         | [--]    | [-------]   | [--]     | [--]          |
| [@hassytrades](/creator/twitter/hassytrades)         | [--]   | [------]    | [--]     | [--]          |

[View More](/list/creators/$nvcr/100)
  
  
### Sentiment: 81%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/sentiment.tsv)  
Current Value: 81%  
Daily Average: 71%  
[--] Week: 73% -27%  
[--] Month: 73% -7%  
[--] Months: 73% -7%  
[--] Year: 73% +21%  
1-Year High: 100% on 2025-02-26  
1-Year Low: 8% on 2026-01-11  

Most Supportive Themes:
- FDA Approval for Pancreatic Cancer Treatment: (50%) NovoCure's Optune Pax device has received FDA approval for treating locally advanced pancreatic cancer, marking a significant advancement in treatment options.
- Positive Clinical Trial Data: (30%) The PANOVA-3 trial demonstrated improved overall survival and extended time to pain progression for patients using Optune Pax, highlighting the therapy's efficacy.
  
Most Critical Themes:
- Market Trends Impacting Price: (70%) Broader market trends are currently exerting downward pressure on NVCR's stock price, overshadowing positive company news and developments.
  
  
  
### Social Dominance: 0.037%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/social_dominance.tsv)  
Current Value: 0.037%  
Daily Average: 0.00648%  
[--] Week: 0.212% +0.21%  
[--] Month: 0.073% +0.069%  
[--] Months: 0.073% +0.068%  
[--] Year: 0.073% +0.06%  
1-Year High: 0.073% on 2026-02-15  
1-Year Low: 0.0003% on 2025-12-21  
  
  
### Market Dominance: 0.0014%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/market_dominance.tsv)  
Current Value: 0.0014%  
Daily Average: 0%  
1-Year High: 0.00879% on 2025-03-31  
1-Year Low: 0.00129% on 2026-02-09  
  
  
### Market Cap: $1,232,921,611
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/market_cap.tsv)  
Current Value: $1,232,921,611  
Daily Average: $1,663,275,554  
[--] Week: $1,233,190,368 +8%  
[--] Month: $1,230,681,971 -20%  
[--] Months: $1,230,681,971 -9%  
[--] Year: $1,230,681,971 -49%  
1-Year High: $2,432,368,236 on 2025-02-16  
1-Year Low: $1,123,179,269 on 2026-02-09  

### Top NovoCure Limited Ordinary Shares Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"🧬 Weekly & YTD Biotech Moves Week ending 02/13/26 $XBI: -2.11% ($122.86) 🔴 $IBB: -1.39% ($172.55) 🔴 Year-to-date $XBI: 0.76% 🟢 $IBB: 2.24% 🟢 See image below. 👇 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune https://t.co/RjwPL6kU1b 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51%"  
[X Link](https://x.com/BiopharmIQ/status/2022674375322018086) [@BiopharmIQ](/creator/x/BiopharmIQ) 2026-02-14T14:08Z 28.9K followers, [----] engagements


"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune Pax for Cancer 📉 $UPB -47% VALIANT Trial Results $MCRB -42% Program and Corporate Updates $CHRS -20% Pricing of Public Offering $1.75/sh $OKYO -19% Pricing of $20M Offering $1.85/sh $RGNX -14% Regulatory Update on RGX-121 BLA See image below. *** AD momentum continues. $NKTR maintenance data + early Ph2a from $EVMN in a"  
[X Link](https://x.com/BiopharmIQ/status/2022672827145650554) [@BiopharmIQ](/creator/x/BiopharmIQ) 2026-02-14T14:02Z 28.9K followers, [----] engagements


"$ERNA offering👇⛔ $BNAI $CHOW $DXST $UOKA $GNLN $AREB $ORKT $JZXN $QNCX $CCHH $KIDZ $RENX $JDZG $KPTI $WORX $SGN $FSLY $LHSW $DRIP $JZ $OCG $PRCH $CGNX $FSLY $COCH $SMX $NCI $SOXS $ELPW $RPGL $OPEN $DJT $BTC $ETH $XRP $DOGE $BTC.X $SPY $AMC $GME $ASTS $SLV $ZSL $NVCR $CCHH"  
[X Link](https://x.com/Stocktology/status/2022448460054827072) [@Stocktology](/creator/x/Stocktology) 2026-02-13T23:11Z [---] followers, [---] engagements


"FDA clears Novocure's wearable Optune Pax therapy for pancreatic cancer $NVCR https://firstwordpharma.com/story/7103267 https://firstwordpharma.com/story/7103267"  
[X Link](https://x.com/fwpharma/status/2022100214467936558) [@fwpharma](/creator/x/fwpharma) 2026-02-13T00:07Z 55.2K followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing